Growth momentum on track—watch new capacity ramp and margin hold
Grasim enters Q2 off a record Q1 (revenue +21%, EBITDA +26% YoY), with three new business engines scaling (Epichlorohydrin plant live, Birla Opus paints, B2B e-commerce breakeven in sight) and promoter confidence crystallizing. Street remains bullish on 16%+ EBITDA upside and full-year guidance, but margin resilience in a mixed cost environment will be key.
What to Expect
Grasim delivered record Q1 FY2027 revenue of ₹48,716 Cr (+21% YoY) and EBITDA of ₹8,077 Cr (+26% YoY, 16% margin), marking the 24th consecutive quarter of revenue growth. The company is guiding for Paints (Birla Opus) >50% revenue growth and B2B e-commerce (Birla Pivot) EBITDA breakeven by end-FY2027. For Q2, expect momentum to largely persist—the question is margin. With new production capacity live (Epichlorohydrin plant started Oct 21), the quarter should show volume growth across Cement, Chemicals, and Fibres. EBITDA margin resilience will hinge on input costs (pulp, fibre feedstock, energy) and realization in international markets.
~₹48–50 Cr
Q1 set ₹48.7 Cr at +21% YoY; Q2 typically softer than Q1 in cement. Assume 18–22% YoY growth.
~16%
Q1 held 16% on higher volumes and product mix. New Epichlorohydrin capacity ramps; margin resilience vs raw material inflation key.
High-teens to mid-20s%
Q1 Adj. PAT +49% YoY on operating leverage and one-offs. Normalize to core run-rate ~20% growth.
Debt/EBITDA ~1.45x
Target maintained below 2.0x through FY27. Continued CP repayments (₹3,050 Cr repaid Sep–Nov) signal comfort.
A strong Q2 print would show revenue at or above ₹49 Cr (+19% YoY+), EBITDA margin stable-to-expanding, and early evidence of Epichlorohydrin plant contributing to Chemicals EBITDA. Weak print would be revenue below ₹48 Cr, EBITDA margin compression below 15%, or guidance qualification on FY27 targets. However, given Q1's record and management's track record, consensus expects the company to deliver on-plan.
On Track?
Yes. Q1 revenue +21% YoY and EBITDA +26% YoY mark the strongest quarter on record. The company is executing its three-part growth plan: (1) Core legacy Cement + Chemicals + Fibres remain stable-to-growing (Cement +16% vol in Q1, Chemicals EBITDA +16% YoY); (2) New capacity is live or imminent (Epichlorohydrin 50,000 TPA started production Oct 21; Solenergi acquisition CCI-cleared Oct 30, adding renewable energy capacity); (3) Growth engines scale (Paints targeting >50% revenue growth YoY with breakeven EBITDA by FY27; B2B e-commerce Birla Pivot breakeven expected by year-end). Net debt/EBITDA at 1.45x vs 1.62x in Q1 FY26 shows balance-sheet discipline. Management has not issued full-year P&L guidance (revenue/EBITDA), so all signals point to confidence in executing on the trajectory.
What the Street Says
Since Last Quarter
Operational progress: Grasim commissioned its Epichlorohydrin (ECH) plant in Vilayat, Gujarat on Oct 21, 2026. Capacity: 50,000 TPA. This is a new specialty chemical product for the company, supporting higher-margin chemical EBITDA. M&A: Subsidiary Aditya Birla Renewables (ABReN) received CCI approval on Oct 30 for the 100% acquisition of Solenergi Power—adding utility-scale renewable energy capacity to the portfolio. Partnerships: Grasim's Advanced Materials Division signed an MoU with Suzlon Energy on Oct 4 to develop recyclable wind turbine blades, broadening the renewables value chain. Debt management: Aggressive CP repayment—₹750 Cr repaid on Sep 24, Sep 18, Oct 26, and Nov 4; ₹800 Cr on Sep 11, Sep 18. Total ~₹3,050 Cr in Q2–Q3. Ownership: Birla Group Holdings (Kumar Mangalam Birla and persons acting in concert) acquired a 4.60% stake in Sep 2026—confidence signal. Regulatory: Bombay HC on Oct 25 quashed a ₹329 Cr tax reassessment notice, a legal win. ESG: CRISIL upgraded ESG rating to 'Crisil ESG 65' (Strong) in Aug 2026, up from 61; NSE rating also improved to 'Aspiring' (65 points). None of these are headwinds; the narrative is progress on new capacity, capital return confidence, and strategic partnerships.
The Setup
GRASIM enters Q2 as a compounder on its best trajectory in years: record Q1, three new business engines scaling, promoter conviction reflected in 4.6% stake buy, and Street consensus unanimously bullish. The stock trades near 52-week lows-to-ATH (-5.4% from ₹3,411), leaving room for re-rating. Q2 will test whether the company can sustain EBITDA margin and convert new capacity into earnings accretion. The real watch is not top-line (that's likely to deliver; Q1 was +21%), but rather margin hold and early evidence that Epichlorohydrin and renewables are scaling as promised.
1 · EBITDA margin hold/expand vs input inflation
Pulp and fibre feedstock costs remain volatile globally. Can Grasim hold 16% EBITDA margin or improve it despite Q2 seasonality? If margin compresses below 15%, it signals raw material headwinds are not being fully offset by pricing/mix.
2 · Epichlorohydrin contribution and ramp guidance
Plant started Oct 21. Q2 will show early production/sales. Look for management commentary on run-rate capacity utilization by year-end and EBITDA impact in H2 FY27.
3 · Paints (Birla Opus) and B2B e-commerce (Birla Pivot) trajectory
Guidance is >50% revenue growth for Paints and breakeven EBITDA by FY27. Q2 will show whether growth is on-plan and profitability path is credible.
4 · Cement volume and pricing dynamics
Cement represented 35%+ of EBITDA in prior years. Q2 typically sees seasonal softness. Monitor volume growth and pricing power given competition and monsoon-driven construction lag.
5 · Solenergi integration timeline and ABReN's runway to profitability
M&A closed ~Oct 30. Look for management's integration plan and updated capital requirements. Any update on when renewables EBITDA turns accretive?
Grasim swings to ₹234 Cr loss in Q2 FY27 on one-off AVNB charge, core profit holds
PAT -139.37% YoY · revenue +25.58% · margins compressing
₹50,105.18 Cr
+25.58% YoY
₹-234.08 Cr
-139.37% YoY
-0.46%
-4.2pp YoY
₹-3.45
Consolidated revenue grew 25.6% YoY and 2.9% QoQ to ₹50,105 Cr for the quarter ended 30 September 2026, but the headline bottom line swung to a net loss of ₹234 Cr attributable to Grasim's own shareholders (basic EPS -₹3.45), against a restated profit of ₹594.5 Cr a year ago and ₹2,145.9 Cr in Q1 FY27. The swing was driven entirely by a ₹766.73 Cr exceptional charge - a ₹128.72 Cr impairment plus a ₹638.01 Cr provision - against Grasim's exposure to AV Group NB Inc (AVNB), the Canadian joint venture that has temporarily idled its dissolving-grade pulp mill at Nackawic, New Brunswick (the equivalent standalone-level charge was ₹825.43 Cr). Strip that out and the group held up: total profit after tax for the period, before the owners/minority split, was ₹1,029.4 Cr, of which ₹1,263.5 Cr accrued to non-controlling shareholders in UltraTech Cement and Aditya Birla Capital - both majority-but-not-wholly-owned subsidiaries that stayed solidly profitable even as the AVNB charge, booked directly at the parent/JV level, wiped out the owners' share.
Q2 FY-2027 vs prior quarters
No formal Street consensus for this print turned up in search, so a beat/miss call isn't possible. Adjusting for the one-off (which had no prior-year equivalent), owners' PAT comes to roughly ₹535-540 Cr, down about 9-10% on the restated ₹594.5 Cr a year ago - a far more modest decline than the headline loss implies, and consistent with group operating margin holding broadly flat YoY at 12.53% (12.46% a year ago) even as it slipped from 16.14% in Q1. Net profit margin fell to 2.05% from 3.95% YoY and 7.99% QoQ, but that compression is a function of the one-off and the owners/NCI split, not core cost or pricing pressure. Growth was broad-based: Financial Services (Aditya Birla Capital) revenue rose 32.4% YoY to ₹13,990 Cr with segment EBIT up roughly 49% YoY; Cellulosic Fibres grew 28.8% YoY to ₹5,343.5 Cr; Building Materials (cement, paints, B2B e-commerce - mainly UltraTech and Birla Opus) grew 23% YoY to ₹27,378 Cr, though its segment EBIT of ₹3,510.5 Cr fell sharply from ₹5,002.3 Cr in Q1 - a sequential slowdown.
The stock went into the print at ₹3,062, up 6.6% over the past month of trading.
Birla Opus targeting ₹10,000 Cr revenue by FY28 with profitability at that scale; FY27 >50% YoY growth. Birla Pivot on track for EBITDA break-even by FY27 exit at ₹10,000+ Cr annualized run rate. Consolidated net debt to maintain below 2x EBITDA. FY27 capex ₹3,157 Cr (45% growth capex).
Management's standing guidance - Birla Opus reaching ₹10,000 Cr revenue by FY28 with FY27 growth above 50%, and Birla Pivot hitting EBITDA breakeven at a ₹10,000+ Cr annualized run-rate by FY27 exit - isn't separately verifiable from this result, since both are folded into the Building Materials and Others segments. The only external data point is Q1 FY27 Birla Opus revenue of ₹1,661 Cr (+64% YoY), tracking ahead of pace, but no Q2-specific Opus figure is disclosed here. No standalone management press release was available to cross-check the quarter's framing against the numbers. On the corporate-action side, Grasim repaid ₹750 Cr of commercial paper twice during the quarter (26 October and 4 November), CCI cleared its renewables subsidiary's acquisition of Solenergi Power (not yet consolidated as of 30 September), and the Bombay High Court quashed a ₹329 Cr tax reassessment - balance-sheet-supportive items alongside a consolidated debt-equity ratio of 1.43x this quarter.
W1
Whether owners'-attributable PAT reverts to the ~₹2,000-2,150 Cr quarterly run-rate seen earlier in FY27 now that AVNB has both an impairment and a ₹638.01 Cr provision recognised against it.
W2
Birla Opus's path to the ₹10,000 Cr FY28 revenue target and >50% FY27 growth guidance - confirm Q3 Opus-specific revenue given Q1's ₹1,661 Cr (+64% YoY) pace.
W3
Birla Pivot's progress toward EBITDA breakeven at a ₹10,000+ Cr annualized run-rate by FY27 exit, and consolidated debt metrics (debt-equity was 1.43x this quarter).
Consolidated figure of -234.08 Cr is PAT attributable to owners (matches reported EPS -3.45); total group PAT incl. non-controlling interest was 1,029.42 Cr (= PBT 2,695.92 - tax 1,666.50), of which 1,263.50 Cr went to NCI in UltraTech/ABCL since the 766.73 Cr AVNB exceptional charge sits at the parent/JV level, not shared with subsidiary NCI; FY26-Q2 comparatives are Ind AS 117-restated (ABHICL) - restated net profit 1,576.32 Cr / owners 594.52 Cr differs from our prior DB record of 1,498.04 Cr.